Spots Global Cancer Trial Database for prostatic neoplasms
Every month we try and update this database with for prostatic neoplasms cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE) | NCT03099031 | Venous Thromboe... | Tinzaparin | 18 Years - | LEO Pharma | |
| Multiparametric MRI in Men With Prostate Cancer Enrolled in Active Surveillance | NCT03648359 | Prostatic Neopl... | multiparametric... | 18 Years - 75 Years | Herlev Hospital | |
| Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC) | NCT00313781 | Prostatic Neopl... | CP-751,871 docetaxel prednisone docetaxel prednisone | 18 Years - | Pfizer | |
| Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy | NCT04833426 | Prostatic Neopl... Hypogonadism Testosterone De... | Testosterone ge... Placebo | 18 Years - | Canisius-Wilhelmina Hospital | |
| Far Infrared Radiation Treatment for Prostate Cancer | NCT00573820 | Prostatic Neopl... | Far Infrared Ra... | - | GAAD Medical Research Institute Inc. | |
| A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer | NCT00672009 | Prostatic Disea... Genital Neoplas... Urogenital Neop... Genital Disease... Adenocarcinoma Prostatic Neopl... Neoplasms, Glan... Carcinoma | Ixabepilone | - | Cedars-Sinai Medical Center | |
| Familial Prostate Cancer | NCT00001377 | Neoplastic Synd... Prostatic Neopl... | - | National Institutes of Health Clinical Center (CC) | ||
| Learning Curve of Digital Rectal Examination for Prostate Cancer Among Internship | NCT03479359 | Prostatic Neopl... Digital Rectal ... Benign Prostati... | Routine review ... | - | Changhai Hospital | |
| MRI-targeted Biopsy of the Prostate: Software Versus Visual Registration in the Accuracy of Prostate Cancer Detection | NCT03819751 | Prostate Cancer Prostate Neopla... | MRI-targeted pr... | 50 Years - 75 Years | Universitaire Ziekenhuizen KU Leuven | |
| 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer | NCT04689828 | Prostatic Neopl... | 177Lu-PSMA-617 68Ga-PSMA-11 ARDT Best supportive... | 18 Years - | Novartis | |
| Gallium-68 Citrate PET Used in Prostate Cancer | NCT02391025 | Prostatic Neopl... | Gallium-68 citr... Positron Emissi... | 18 Years - | University of California, San Francisco | |
| Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | NCT02014337 | Breast Cancer Ovarian Epithel... Sarcoma Non-small Cell ... Carcinoma, Tran... Prostate Cancer Prostatic Neopl... | Mifepristone an... | 18 Years - | Corcept Therapeutics | |
| Tissue Predictors of Abiraterone Benefit | NCT03176381 | Metastatic Cast... | 18 Years - | Tianjin Medical University Second Hospital | ||
| PRIME - PRostate Imaging for Margin Evaluation | NCT02151097 | Prostatic Neopl... | 18 Years - | Lightpoint Medical Limited | ||
| Impact on Quality of Life and Health of the CONTINUUM+ CONNECT Remote Monitoring Solution | NCT06379880 | Prostatic Neopl... Lung Neoplasms Breast Neoplasm... Colorectal Neop... | CONTINUUM+ CONN... | 18 Years - | Institut de cancérologie Strasbourg Europe | |
| A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer | NCT00564928 | Prostate Cancer Prostatic Neopl... Cancer of the P... | IPI-504 | 18 Years - | Infinity Pharmaceuticals, Inc. | |
| Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer | NCT00381836 | Prostatic Neopl... Anemia | Darbepoetin Alf... | 18 Years - | University of Aarhus | |
| A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) | NCT06136598 | Prostatic Neopl... Metastatic Cast... | Opevesostat Dexamethasone Fludrocortisone Hydrocortisone | 18 Years - | Merck Sharp & Dohme LLC | |
| Rectal Gas Removal Through Small Catheter Placement Prior to MRI of the Prostate | NCT03987737 | Prostatic Neopl... Prostate Cancer | small urinary c... | 45 Years - 80 Years | Universitaire Ziekenhuizen KU Leuven | |
| Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer | NCT00906269 | Impotence Prostatic Neopl... | Sildenafil ther... Sildenafil ther... | 40 Years - 65 Years | Hartford Hospital | |
| A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | NCT02905201 | Prostatic Neopl... | 18 Years - | Janssen Research & Development, LLC | ||
| A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases | NCT04523207 | Prostatic Neopl... | Apalutamide ADT Relugolix | 18 Years - | Janssen Research & Development, LLC | |
| Exisulind Prior to Radical Prostatectomy | NCT00166478 | Prostatic Neopl... | Exisulind Thera... | 40 Years - | Mayo Clinic | |
| Feasibility Study for the Assessment of Sleep Quality in Men With Prostate Cancer Starting ADT | NCT02919904 | Prostatic Neopl... Sleep | ARESTM | 18 Years - | Vancouver Prostate Centre | |
| An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT02257736 | Prostatic Neopl... | Apalutamide Abiraterone ace... Prednisone Placebo | 18 Years - | Aragon Pharmaceuticals, Inc. | |
| Protection of Rectum From High Radiation Doses Using a Spacer | NCT01918605 | Prostatic Neopl... Genital Neoplas... Urogenital Neop... Neoplasms by Si... | Diluted spacer Non-diluted spa... | 50 Years - 78 Years | University of Oulu | |
| An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer | NCT00748358 | Prostatic Neopl... Neoplasms, Horm... Tumor Markers, ... Survival Rate Disease-Free Su... | sunitinib | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Taxotere Prostate Cancer New Indication Registration Trial in China | NCT00436839 | Prostatic Neopl... | Docetaxel Mitoxantrone Prednisone | - | Sanofi | |
| Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer | NCT00489905 | Prostatic Neopl... Bone Density | Zolderonic acid... | 50 Years - 80 Years | Hospital Authority, Hong Kong | |
| Effect of Modified Citrus Pectin on PSA Kinetics in Biochemical Relapsed PC With Serial Increases in PSA | NCT01681823 | Prostatic Neopl... | PectaSol-C Modi... | 21 Years - | EcoNugenics | |
| Selenium and Prostate Cancer: Clinical Trial on Availability to Prostate Tissue and Effects on Gene Expression | NCT00446901 | Prostatic Neopl... Prostate Cancer | Selenium | - | Wageningen University | |
| Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma | NCT02234115 | Prostatic Neopl... | Leuprolide Mesy... | 18 Years - | Foresee Pharmaceuticals Co., Ltd. | |
| Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer | NCT01995058 | Prostate Cancer Castration Resi... Prostatic Neopl... | cabozantinib abiraterone prednisone | 18 Years - | Exelixis | |
| A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer | NCT04644770 | Prostatic Neopl... Adenocarcinoma | JNJ-69086420 | 18 Years - | Janssen Research & Development, LLC | |
| Prostate Impendance Test Project | NCT03428087 | Prostatic Neopl... PSA Prostatic Biops... Impedance Test | 45 Years - | University of Pisa | ||
| Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer | NCT00941915 | Prostate Cancer | SBRT Prostate | 40 Years - 82 Years | Duke University | |
| P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) | NCT04249947 | Prostatic Neopl... Neoplasms by Hi... Neoplasms, Pros... Prostate Cancer Metastatic Cast... Neoplasms Prostatic Neopl... Genital Neoplas... Urogenital Neop... Neoplasms by Si... Prostatic Disea... Salivary Gland ... Salivary Gland ... Adenoid Cystic ... Salivary Duct C... Mucoepidermoid ... Acinic Cell Tum... | P-PSMA-101 CAR-... Rimiducid | 18 Years - | Poseida Therapeutics, Inc. | |
| A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) | NCT02034552 | Prostatic Neopl... | Radium-223 dich... Abiraterone ace... Prednisone Enzalutamide | 18 Years - | Bayer | |
| Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer | NCT02446444 | Prostatic Neopl... | Enzalutamide Conventional NS... LHRHA External Beam R... | 18 Years - | University of Sydney | |
| Verification of Shear Wave Elastography for DEtection of Prostate Cancer | NCT04836949 | Prostatic Neopl... | Shear Wave Elas... Conventional Pr... | 21 Years - 90 Years | Yonsei University | |
| Figitumumab Combined With Pegvisomant For Advanced Solid Tumors | NCT00976508 | Colorectal Neop... Lung Neoplasms Breast Neoplasm... Prostatic Neopl... Sarcoma | figitumumab pegvisomant | 10 Years - | Pfizer | |
| Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment | NCT01198457 | Breast Neoplasm... Prostatic Neopl... Multiple Myelom... Osteolysis | Clodronate (Bon... | 18 Years - | Bayer | |
| Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer | NCT00521274 | Prostatic Neopl... | MVA 5T4 Docetaxel | 18 Years - | The Methodist Hospital Research Institute | |
| Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer | NCT01995058 | Prostate Cancer Castration Resi... Prostatic Neopl... | cabozantinib abiraterone prednisone | 18 Years - | Exelixis | |
| Ion Prostate Irradiation | NCT01641185 | Prostatic Neopl... | radiation | 40 Years - 80 Years | Heidelberg University | |
| Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC) | NCT02443571 | Prostatic Neopl... | Fluciclovine (1... | 18 Years - | Blue Earth Diagnostics | |
| Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer | NCT01186601 | Neoplasms | PET tracer (BAY... | 18 Years - 90 Years | Life Molecular Imaging SA | |
| Atorvastatin Before Prostatectomy and Prostate Cancer | NCT01821404 | Prostatic Neopl... | Atorvastatin Placebo | 40 Years - 80 Years | Tampere University Hospital | |
| Evaluation of Length and Quality of Prostate Biopsies Taken by a New Biopsy Needle | NCT04880681 | Prostate Cancer... | Novel needle (1... Standard Tru Cu... | 40 Years - | Region Skane | |
| MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011) | NCT00302471 | Prostatic Neopl... | Comparator: MK0... Comparator: MK0... Comparator: MK0... Comparator: MK0... | 18 Years - | Merck Sharp & Dohme LLC | |
| Cone Beam CT for Daily Image Guidance - Prostate Cancer | NCT00188786 | Prostatic Neopl... | daily Cone Beam... | 18 Years - | University Health Network, Toronto | |
| Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases | NCT01516762 | Prostatic Neopl... | Radium-223 dich... | 18 Years - | Bayer | |
| Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448 | NCT01132404 | Prostate Cancer Prostatic Neopl... | Leuprorelin TAK-448 | 40 Years - 72 Years | Millennium Pharmaceuticals, Inc. | |
| Laser Fluorescence in Cancer Surgical Treatment | NCT03021200 | Esophageal Canc... Gastric Cancer ColoRectal Canc... Prostatic Neopl... Uterine Cancer Head and Neck C... Breast Neoplasm | Green indociani... | 18 Years - | Instituto do Cancer do Estado de São Paulo | |
| Men at High Genetic Risk for Prostate Cancer | NCT03805919 | Prostatic Neopl... | 30 Years - 75 Years | National Institutes of Health Clinical Center (CC) | ||
| Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance | NCT00482157 | Prostatic Neopl... Prostate Cancer | Vitamin D (Calc... | 45 Years - | Stanford University | |
| [Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer | NCT06229366 | Prostate Cancer Metastatic Cast... Biochemically R... | [Ac-225]-PSMA-6... [Ac-225]-PSMA-6... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| Outpatient Radical Prostatectomy - Surgical and Anesthetic Considerations | NCT01955863 | Prostatic Neopl... | patient dischar... patient dischar... patient dischar... | 40 Years - 75 Years | Barretos Cancer Hospital | |
| Stereotactic Radiotherapy for Oligometastatic Prostate Cancer | NCT02563691 | Prostatic Neopl... | stereotactic ra... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139 | NCT02362464 | Prostatic Neopl... Neoplasms of Pr... Prostate Cancer Cancer Of Prost... Stage D0 Prosta... | Multi-epitope (... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer | NCT00537381 | Prostatic Neopl... | Docetaxel Prednisone Intetumumab Placebo | 18 Years - | Centocor, Inc. | |
| Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy | NCT01450683 | Prostate Cancer Prostatic Neopl... Castrate-resist... Androgen-insens... Hormone-refract... Metastatic Dise... | Itraconazole | 18 Years - | Stanford University | |
| Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer | NCT00861471 | Prostate Cancer Prostatic Neopl... | Docetaxel Imatinib Mesyla... | 18 Years - | NYU Langone Health | |
| Evaluation of An Online Intervention In Improving General Practitioners' Practice In Prostate Cancer Screening | NCT03633214 | Prostate Cancer... | Online training... | - | University of Malaya | |
| HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer | NCT01913106 | Prostatic Neopl... | HSV-tk +Valacyc... | - | The Methodist Hospital Research Institute | |
| Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases | NCT01516762 | Prostatic Neopl... | Radium-223 dich... | 18 Years - | Bayer | |
| Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer | NCT01576029 | Prostatic Neopl... | CABAZITAXEL (XR... DOCETAXEL (XRP6... | 18 Years - | Sanofi | |
| Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists | NCT02475057 | Prostatic Neopl... Cardiovascular ... | Degarelix (LHRH... LHRH agonist EndoPAT2000 | 18 Years - 90 Years | Rabin Medical Center | |
| Multiparametric MRI in Men With Prostate Cancer Undergoing Active Surveillance | NCT02526797 | Prostatic Neopl... | 18 Years - 75 Years | Herlev Hospital | ||
| Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer | NCT00040365 | Prostatic Neopl... | Amifostine trih... Radiation thera... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy | NCT04461509 | Prostatic Neopl... Genital Neoplas... Urogenital Neop... Neoplasms by Si... Neoplasms Genital Disease... Prostatic Disea... | 18F-PSMA | 18 Years - | Cedars-Sinai Medical Center | |
| The Detection of Circulating Tumor Cells (CTCs) in Patients With Prostatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment | NCT02450435 | Neoplastic Cell... | Flow cytometry ... RT-PCR | 18 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | |
| Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2 | NCT00040586 | Prostatic Neopl... | Monoclonal Anti... Recombinant Int... | 21 Years - | BZL Biologics | |
| The Detection of Circulating Tumor Cells (CTCs) in Patients With Prostatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment | NCT02450435 | Neoplastic Cell... | Flow cytometry ... RT-PCR | 18 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | |
| Irreversible Electroporation(IRE) For Unresectable Prostatic Neoplasms | NCT02430649 | Prostatic Neopl... | Irreversible el... NanoKnife | - | Fuda Cancer Hospital, Guangzhou | |
| An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer | NCT00748358 | Prostatic Neopl... Neoplasms, Horm... Tumor Markers, ... Survival Rate Disease-Free Su... | sunitinib | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer | NCT04557059 | Prostatic Neopl... | Radiotherapy LHRHa Apalutamide | 18 Years - | Janssen Pharmaceutica N.V., Belgium | |
| First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer | NCT01723475 | Prostatic Neopl... | BAY2010112 BAY2010112 | 18 Years - | Bayer | |
| A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy | NCT00096551 | Prostatic Neopl... | Recombinant Vac... Recombinant Fow... Recombinant Fow... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer | NCT01420965 | Prostatic Neopl... | CT-011 (Anti-PD... Sipuleucel-T (P... Cyclophosphamid... | 18 Years - | Augusta University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
